Sign In   |   Register
The EAS-FH Studies Collaboration (FHSC)
 

EAS FH Studies Collaboration - a global call to action

 

Familial Hypercholesterolaemia

Familial Hypercholesterolaemia (FH) represents a major global health problem because, despite being very common, it is widely underdiagnosed, undertreated and, as a result often fatal. The consequences of FH in the form of premature atherosclerosis and cardiovascular events are potentially preventable, but require effective initiatives and policies to address the current issues and reduce the burden of disease.

EAS FHSC initiative

To address these issues, FH investigators from all over the world have come together under the EAS FH Studies Collaboration (FHSC) since 2015, to initiate a global call to take action. EAS FHSC aims to raise awareness on the disease and encourage the development of programmes, initiatives and policies specifically focused on FH, by joining efforts from healthcare providers, patient organizations, policy makers and the entire medical community. This call to action is described in an article published in Atherosclerosis, providing a framework for further work that needs to be undertaken to reduce the impact of FH and the global burden of the disease. 1

EAS FHSC Mission Statement

"The mission of the EAS-FHSC is to empower the medical & global community to seek changes in their respective countries or organizations regarding how FH is detected and managed, with a view to promoting early diagnosis and more effective treatment of this condition. Through international collaboration of stakeholders EAS FHSC aims to generate large scale robust data on how FH is detected, managed and the clinical consequences of current practice on outcomes."

Professor Kausik Ray
Imperial College London, UK
Lead FHSC
Professor Alberico L. Catapano
University of Milano, Italy
Past President EAS

 

EAS FHSC objectives

The EAS FHSC aims to etablish the first global FH Registry of patients with FH, to:

  1. Generate robust information to accurately and reliably investigate the burden of both homozygous and heterozygous FH, how FH is detected and managed, and the clinical consequences of current practices on delivery of care and outcomes.
  2. To disseminate the information gained from the registry to an international audience including physicians, other helthcare professionals, policy-makers and patients´organizations.
  3. To consolidate a network of investigators interested in FH through which collaborative research and networking on FH can be conducted on a large-scale.

The FHSC methods paper was published in Atherosclerosis in 2016, describing the rationale, the design and the methods of the EAS-FHSC project and registry.2 

EAS FHSC Network

EAS-FHSC is a global initiative led by Prof Kausik Ray (Imperial College London, UK) and an executive committee comprising Prof Alberico L. Catapano (Italy); Dr. Tomas Freiberger (Czech Republic); Prof John Kastelein, Prof G.Kees Hovingh (Netherlands); Prof Pedro Mata (Spain); Dr Handrean Soran (UK); Prof Gerald Watts (Australia); Prof Frederick Raal (South Africa) and Prof Raul Santos (Brazil).
The Coordinating Centre for the EAS FHSC is based at the Imperial Centre for Cardiovascular Disease Prevention (ICCP), School of Public Health, Imperial College London, UK.
To ensure the smooth operation within the network, the EAS FHSC collaboration is supported by a number of FH Lead Investigators for their respective countries. Currently, ca. 70 countries and more than 80 Lead investigators are involved. An overview of the current situation related to FH in the involved country has been presented in the FHSC overview article, the first global survey on FH status, published this year in Atherosclerosis.3

Read the articles

  1.  Vallejo-Vaz, Antonio J. et al. Familial Hypercholesterolaemia: A global call to arms. Atherosclerosis. http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.021
  2. EAS Familial Hypercholesterolaemia Studies Collaboration, Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies CollaborationAtherosclerosis Supplements 2016;22:1-32.
    http://www.atherosclerosis-supplements.com/issue/S1567-5688(16)X0003-7
  3. EAS Familial Hypercholesterolaemia Studies Collaboration, Overview of the current status of familial hypercholesterolaemia care in over 60 countries- the EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis - to be published September 24, 2018.
Membership Software Powered by YourMembership  ::  Legal